Clinical Trial Update: Safety and Efficacy of MK-6096 as Adjunctive Therapy in Participants With Major Depressive Disorder And Partial Response to Antidepressant Monotherapy (MK-6096-022) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for MK-6096 as adjunctive therapy in participants with major depressive disorder and partial response to antidepressant monotherap…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• MK-6096

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Major Depressive Disorder, Recurrent | Phase 2 | Status: TERMINATED | Results posted: 2016-11-07